PAPP-A: a promising therapeutic target for healthy longevity.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28035757.
- Also identified by DOI 10.1111/acel.12564 and PMC identifier 5334524.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pregnancy-associated plasma protein-A (PAPP-A) is a proteolytic enzyme that was discovered to increase local insulin-like growth factor (IGF) availability for receptor activation through cleavage of inhibitory IGF binding proteins (IGFBPs). Reduced IGF signaling has been associated with increased lifespan and healthspan. Therefore, inhibition of PAPP-A represents a novel approach to indirectly decrease the availability of bioactive IGF. Here, we will review data in support of PAPP-A as a therapeutic target to promote healthy longevity.
Medical subject headings
- Health
- Longevity
- Molecular Targeted Therapy
- Pregnancy-Associated Plasma Protein-A